Bristol-Myers Squibb pays $14 million to resolve China FCPA offenses

by -
By Richard L. Cassin, Published on The FCPA Blog on October 5th, 2015 The Securities and Exchange Commission said Monday that Bristol-Myers Squibb agreed to settle charges that its joint venture in China made cash payments and provided other benefits to health care providers at state-owned and state-controlled hospitals in exchange for prescription sales. –…

Hitachi Inspires The Next FCPA Enforcement Action Against A Foreign Company

by -
Published on The FCPA Professor, September 29th, 2015 What happens when a Japanese company has a German-based subsidiary, which in turn has a South African subsidiary, that both allegedly make improper payments to a South African political party? Why of course, $19 million to the U.S. treasury because the Japanese company just happened to have American…

China amends its Criminal Law: Impact on anti-bribery enforcement

by -
By Eric Carlson and Ping An, Published on The FCPA Blog on September 1st, 2015. On August 29, China’s National People’s Congress (NPC) adopted a slate of amendments to the country’s Criminal Law . . .  [ Read More ] Related Event: The American Conference Institute’s fourth annual Asia-Pacific Summit on Anti-Corruption, Compliance and Risk Management will address innovations…